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A B S T R A C T
ADNP syndrome is an intellectual disability associated with Autism spectrum disorder caused by mutations in ADNP. We generated an iPSC line from an ADNP
syndrome pediatric patient harboring the mutation p.Trp719* (GENYOi004-A). Peripheral blood mononuclear cells were reprogrammed using a non-transmissible
form of Sendai viruses expressing the four Yamanaka factors (Oct3/4, SOX2, KLF4 and c-MYC). Characterization of GENYOi004-A included mutation analysis of
ADNP by allele-specific PCR, genetic identity by Short Tandem Repeats polymorphism profiling, alkaline phosphatase enzymatic activity, expression of pluripotency-
associated factors and pluripotency studies in vivo. GENYOi004-A will be useful to evaluate ADNP syndrome alterations at early developmental stages.
Resource table.
Unique stem cell line id-
entifier
GENYOi004-A
Alternative name(s) of
stem cell line
ASD-PBMC-iPS4F2
Institution Gene Regulation, Stem Cells and Development Group,
GENYO: Centre for Genomics and Oncological Research
Pfizer-University of Granada-Junta de Andalucía, PTS,
Granada 18,016, Spain;
Contact information of
distributor
Pedro J. Real: pedro.real@genyo.es
Jose L. Fernández-Luna: joseluis.fernandez@scsalud.es
Type of cell line iPSC
Origin Human
Additional origin info Age: 8
Sex: Female
Ethnicity: Spaniard Caucasian
Cell Source Blood
Clonality Clonal
Method of reprogram-
ming
Sendai Virus (Cytotune iPS 2.0 Reprograming System)
Genetic Modification YES
Type of Modification Spontaneous mutation
Associated disease ADNP Syndrome
Gene/locus pTyr719* mutation in ADNP gene
Method of modification N/A
Name of transgene or r-
esistance
N/A
Inducible/constitutive s-
ystem
N/A
Date archived/stock date September 2017
Cell line repository/bank hpscreg.eu/user/cellline/edit/GENYOi004-A
Ethical approval Comisión de Garantías para la Donación y Utilización de
Células y Tejidos Humanos. Junta de Andalucia.
PR-05-2017
Resource utility
GENYOi004-A is the first iPSC line generated from ADNP syndrome
patients. GENYOi004-A will be a very useful tool to understand ADNP
syndrome alterations at early developmental stages and to test experi-
mental treatments for these patients in vitro.
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Resource details
Autism spectrum disorder (ASD) is a developmental disorder char-
acterized by alterations in communication and behavior. Several ASD
genes have been recently identified (De Rubeis et al., 2014; Iossifov
et al., 2014). Mutations in Activity-Dependent Neuroprotective Protein
gene (ADNP) have been associated with Helsmoortel-Van der Aa Syn-
drome (OMIM: 615873) (Helsmoortel et al., 2014), also known as
ADNP syndrome that is considered an ASD. We have generated an iPSC
line from peripheral blood mononuclear cells (PBMCs) obtained from
an ADNP syndrome pediatric patient carrying a de novo
p.Trp719*mutation (Mollinedo et al., 2019). This new iPSC line was
named ASD-PBMC-iPS4F2 (registered as GENYOi004-A at www.
hPSCreg.com). In parallel, we also generated an iPSC line from her
mother (PBMC2-iPS4F8) that does not harbor any mutation in ADNP
and will be consider as a negative control for genetic assays.
Our group has a broad experience on the use of CytoTune iPS 2.0
Reprograming System (Life Technologies, Invitrogen) to reprogram
PBMCs from donors and patients. PBMCs from the ADNP patient and
her mother were exposed to Sendai virus vectors (SeV) expressing the
reprogramming factors Oct3/4, SOX2, KLF4 and c-MYC. 3 weeks after
transduction several clones were selected and characterized as de-
scribed below.
Firstly, we determined the presence of the mutation p.Trp719* in
ADNP by allele specific PCR from genomic DNA in both cell lines,
GENYOi004-A and PBMC2-iPS4F8 (Mollinedo et al., 2019) (Fig. 1A).
Next, Short Tandem Repeat polymorphism (STR) analysis confirmed
the same genetic identity between PBMCs from the patient (ASD-
PBMCs) and GENYOi004-A (Table 1). GENYOi004-A cells silenced the
expression of exogenous reprogramming transgenes (Fig. 1B) and ac-
tivated the expression of the endogenous pluripotent transcription
factors, SOX2, REX1, NANOG and OCT4 (Fig. 1C) at passage 4.
Importantly, GENYOi004-A cells showed normal karyotype at passage 7
(46, XX) (Fig. 1D). This new cell line grows forming typical round-
shaped colonies and shows alkaline phosphatase activity (Fig. 1E).
Moreover, expression of the pluripotent markers SSEA3, SSEA4,
Tra1–60, Tra1–81 and OCT3/4 was evaluated by flow cytometry ana-
lysis (Fig. 1F). Finally, functional pluripotency was assessed in vitro (by
embryo body formation) (Fig. 1G) and in vivo (teratoma formation as-
says) (Fig. 1H). In both cases, GENYOi004-A cells generate embryo
bodies (EBs) and teratomas containing all three germ layers: ectoderm
(GFAP or β3-Tubulin), mesoderm (Vimentin) and endoderm (Cytoker-
atin CK AE1-AE) as shown in Fig. 1G and H.
Materials and methods
Generation of GENYOi004-A and PBMC2-iPS4F8 lines
Peripheral blood sample was obtained from a pediatric patient with
ADNP syndrome and her mother after informed consent according with
the Andalusian Ethics Review Board for Cellular Reprogramming re-
quirements and with Spanish and EU legislation. PBMCs were isolated
by centrifugation using Ficoll Paque™ PLUS (GE Healthcare). Isolated
mononuclear cells were cultured in StemSpan™ SFEM (StemCell
Technologies) supplemented with hSCF, hFLT3L, hTPO, G-CSF and hIL3
(Peprotech) for four days, transferred to a 12-well fibronectin coated
plate (BD BioCoat™) and exposed to Sendai virus (SeV) (CytoTune®-iPS
2.0 Reprogramming kit, Life Technologies, Invitrogen) as formerly de-
scribed (Lopez-Onieva et al., 2016). One month after reprogramming
GENYOi004-A and PBMC2-iPS4F8 lines were adapted to grow in Es-
sential 8 growth medium on Matrigel (BD Bioscience). Cells were split
at a ratio from 1:6 to 1:8 every 4–5 days using PBS/EDTA (0.5M) and
cultured in a conventional incubator (37 °C, 5% CO2).
Fig. 1. (A) Allele-specific PCR from GENYOi004-A, PBMC2-iPS4F8 and PBMCs from a healthy donor (Control PBMCs). Amplification of the b-Actin gene was used as
a control. (B) Silencing of exogenous reprogramming factors and SeV vector confirmed by RT-PCR. PBMCs transduced cells from the patient at day 4 after Sendai
virus exposure was used as a positive control. (C) Expression of the endogenous pluripotent transcription factors SOX2, REX1, NANOG and OCT 3 was assessed by RT-
PCR. Human embryonic stem cell H9 was used as positive control. (D) GTG-banding shows a normal karyotype in GENYOi004-A cell line. (E) Alkaline phosphatase
enzymatic activity staining. (Scale bar = 150 μm). (F) Expression of pluripotency-associated markers SSEA3, SSEA4, TRA1-81, TRA 1-60 and OCT3/4 at protein level
by FACS analysis. The inset shows the staining of the isotype-matched antibody. (G) Embryo body (EB) differentiation assay. Immunohistochemistry analysis for
endoderm (CKAE1-AE3), mesoderm (Vimentin) and ectoderm (β-III-Tubulin) from 3 week developed EBs. (Scale bar = 100 mm) (H) In vivo differentiation test by
teratoma formation assay. Histological sections from 15 week-teratomas developed in the dorsal flanks of NOD/LtSz-scid interleukin-2Rγ_/_ mice following injection
with ASD-PBMC-iPS4F2 cells. Hematoxylin and eosin (H&E) staining and immunohistochemistry analysis showed differentiation to endoderm (CK AE1-AE3), me-
soderm (Vimentin) and ectoderm (GFAP). (Scale bar = 250 μm).
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Visual record of the line: normal Fig. 1 panel E
Phenotype Qualitative analysis (RT-PCR) Positive for SOX2, REX1, NANOG and OCT4 Fig. 1 panel C
(Alkaline Phosphatase staining) Positive Fig. 1 panel E
Quantitative analysis (Flow
cytometry)
Oct3/4: 80%Tra 1–60: 96%; Tra1–81:30%; SSEA-4: 99%;
SSEA-3: 37%
Fig. 1 panel F
Genotype Karyotype (G-banding) and
resolution
46, XX
Resolution 450–500
Fig. 1 panel D
Identity STR analysis 16 loci tested, all matched Available with the authors
Mutation analysis (IF APPLICABLE) Allele specific PCR Specific amplication of mutant ADNP in ASD-PBMC-iPS4F4 Fig. 1 panel A
Southern Blot OR WGS
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR
Negative
Supplementary file 2
Differentiation potential Embryoid body formation Immunohistochemistry for Vimentin, CK-AE1-AE3, β-III-
tubulin
Fig. 1 panel G
Teratoma formation Immunohistochemistry for Vimentin, CK-AE1-AE3, GFAP Fig. 1 panel H
Donor screening (OPTIONAL) HIV 1+2 Hepatitis B, Hepatitis
C
Negative Not shown but available with
author
Genotype additional info (OPTIONAL) Blood group genotyping N/A
HLA tissue typing HLA-I A* 03/24 - B* 35/55 - C*
HLA-II DRB1* 1401/1401 - DQA1* 01/01 - DQB1* 0503/
0503
Not shown but available with
author
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Allele-specific PCR
Genomic DNA was isolated from GENYOi004-A and PBMC2-iPS4F8
lines using the DNA extraction kit (Qiagen). DNA purified from PBMCs
from a healthy donor not related to the patient was used as a wildtype
control. PCR amplification with a set of primers that specifically re-
cognizes wildtype or mutant alleles (Set ADNP, see Table 2) was per-
formed in all three samples following the manufacturer's instructions
(KapaBiosystems) in a SureCycler 8800 thermal cycler (Agilent). The
PCR conditions were: 5min (95 °C) initial denaturation, 35 cycles (30 s
95 °C denaturation, 30 s 55 °C annealing, 30 s 72 °C extension) followed
by a 7-min final extension segment. The resulting PCR products were
size fractionated onto a 2% agarose gel and stained with ethidium
bromide.
Short Tandem Repeat polymorphism (STR) profiling
The genetic identity of PBMCs from the ASD patient (ASD-PBMC)
and GENYOi004-A was determined as previously described (Lopez-
Onieva et al., 2016) (Table 1).
Semiquantitative RT-PCR
Total RNA from undifferentiated GENYOi004-A line and the human
embryonic stem cell H9 (positive control) line was isolated using the
High pure RNA isolation kit (Roche). cDNA was generated using the
Transcription First Strand c-DNA synthesis kit (Roche) following the
manufacturer's instructions. PCR was performed using GoTaq Flexi
DNA Polymerase kit (Promega). The PCR conditions were optimized to
get semiquantitative data within the linear range of amplification in a
SureCycler 8800 thermal cycler (Agilent). The PCR conditions were:
2min (95 °C) initial denaturation, 30–35 cycles (30 s 95 °C denatura-
tion, 30 s 55–60 °C annealing, 30 s 72 °C extension) followed by a 5-min
final extension segment. PCR products were electrophoresed in an
agarose gel. For exogenous gene clearance analysis (Fig. 1B), PBMCs
transduced cells from the patient at day 4 after Sendai virus exposure
was used as a positive control. H9 hESCs cells were used as a positive
control for endogenous pluripotent transcription factors.
Table 2
Reagents details.
Antibodies used for immunocytochemistry/flow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Rabbit anti-SSEA3-PE 1:100 eBioscience Cat# 12–8833-42
RRID:AB_10854121
Pluripotency Markers Rabbit anti-SSEA4-PE 1:100 BD Pharmingen Cat# 560128
RRID:AB_1645533
Pluripotency Markers Rabbit anti-Tra1–60-PE 1:100 eBioscience Cat# 12–8863-82
RRID:AB_891602
Pluripotency Markers Rabbit anti-Tra1–81-PE 1:100 BD BioScience Cat# 560161
RRID:AB_1645540
Pluripotency Markers Mouse anti-OCT4 1:100 BD BioScience Cat# 611203
RRID:AB_398737
Secondary antibodies Goat Anti-Mouse IgG/IgM FITC 1:200 BD BioScience Cat# 554001
RRID:AB_395197
Isotype control PE Mouse IgM, PE conjugated 1:100 BD BioScience Cat# 555584
RRID:AB_395960
Differentiation Markers Mouse Anti-CKAE1-AE3 1:50 DAKO Cat # M3515
RRID:AB_2132885
Differentiation Markers Mouse Anti-Vimentin (V9) Ready to use Roche Tissue Diagnostics
Cat # 790–2917 RRID: N/A
Differentiation Markers Mouse Anti-β-III-Tubulin 1:50 Millipore Cat # MAB1637
RRID:AB_2210524
Differentiation Markers Mouse Anti-GFAP 1:200 DAKO Cat # M0761
RRID:AB_2109952
Primers
Target Forward/Reverse primer (5′-3′)
Sendai Virus Plasmids (RT-PCR) SeV
(181 bp)
Forward: GGATCACTAGGTGATATCGAGC
Reverse:ACCAGACAAGAGTTTAAGAGATATGTATC
Sendai Virus KOS Plasmid (RT-PCR) KOS
(528 bp)
Forward: ATGCACCGCTACGACGTGAGCGC
Reverse: ACCTTGACAATCCTGATGTGG
Sendai Virus c-MYC Plasmid (RT-PCR) c-MYC
(532 bp)
Forward: TAACTGACTAGCAGGCTTGTCG
Reverse: TCCACATACAGTCCTGGATGATGATG
Sendai Virus KLF4 Plasmid (RT-PCR) KLF4
(410 bp)
Forward: TTCCTGCATGCCAGAGGAGCCC
Reverse: AATGTATCGAAGGTGCTCAA
Targeted mutation analysis: Allele specific PCR ADNP
(206 bp)
Forward (wildtype): CACCTGTGAAGCGCACTTAC
Forward (Mutant): CACCTGTGAAGCGCACTTAA
Reverse: GGGATAGGGCTGTTTGTTGAA
House-Keeping Genomics (RT-PCR) β-ACTIN
(232 bp)
Forward: GCGGGAAATCGTGCGTGACATT
Reverse: GATGGAGTTGAAGGTAGTTTCGTG
Pluripotency Markers (RT-PCR) NANOG
(96 bp)
Forward: TGCAGTTCCAGCCAAATTCTC
Reverse: CCTAGTGGTCTGCTGTATTACATTAAGG
Pluripotency Markers (RT-PCR) OCT4
(110 bp)
Forward: AGTGAGAGGCAACCTGGAGA
Reverse: ACACTCGGACCACATCCTTC
Pluripotency Markers (RT-PCR) REX1
(306 bp)
Forward: CAGATCCTAAACAGCTCGCAGAAT
Reverse: GCGTACGCAAATTAAAGTCCAGA
Pluripotency Markers (RT-PCR) SOX2
(80 bp)
Forward: TCAGGAGTTGTCAAGGCAGAGAAG
Reverse: CTCAGTCCTAGTCTTAAAGAGGCAGC
House-Keeping Gene (RT-PCR) β-ACTIN
(165 bp)
Forward: CTGGAACGGTGAAGGTGACA
Reverse: AAGGGACTTCCTGTAACAATGCA
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Karyotyping
Chromosomal analysis from GENYOi004-A at passage 7 was per-
formed by GTG-banding analysis at the Andalusian Public Health
System Biobank, Spain. 20 metaphases were analyzed according to the
International System Cytogenetics Nomenclature recommendations.
Alkaline phosphatase
GENYOi004-A colonies were assayed for phosphatase alkaline en-
zymatic activity using a commercial detection kit (Merck-Millipore)
following manufacturer's instructions.
Flow cytometry analysis
GENYOi004-A colonies were dissociated using Tryple Express (Life
Technologies) and the cell suspension was stained for SSEA3 (PE,
BioScience), SSEA4 (Alexa Fluor® 647, BD Pharmingen), Tra1–60 (PE,
BioScience), Tra1–81 (Alexa Fluor® 647, BD Pharmingen) and OCT3/4
(BD BioScience) as previously published (Lopez-Onieva et al., 2016). A
relevant isotype-match antibody was always used as a negative control.
Live cells were identified by 7-aminoactinomycin D exclusion and were
analyzed using a FACS verse (BD Bioscience).
Embryo body differentiation assay
GENYOi004-A cells were gently scraped off centrifuged, re-
suspended into Essential 6 medium and plated over low attachment 6-
well plates (Corning) and embryo bodies were formed spontaneously.
Three weeks later, embryo bodies were centrifuged, fixed and em-
bedded in paraffin. Immunocytochemistry analysis were completed as
previously described (Lopez-Onieva et al., 2016).
In vivo teratoma formation
GENYOi004-A cells were dissociated with collagenase IV
(Invitrogen) and resuspended in PBS supplemented with 30% matrigel.
2 million cells were subcutaneously injected into the dorsal flanks of
NOD/LtSz-scid interleukin-2Rγ_/_ mice (The Jackson Laboratory). At
week 15, teratomas were removed, fixed in formaldehyde and em-
bedded in paraffin. Immunocytochemistry analysis confirmed the pre-
sence of ectodermal (β3-Tubulin), mesodermal (Vimentin) and en-
dodermal (CKAE1-AE3) tissues.
Mycoplasma testing
Mycoplasma detection analysis from GENYOi004-A cells was per-
formed by quantitative PCR analysis (Venor GeM-qEP (Minerva
Biolabs)) at the Genomics and Genotyping Unit in GENyO, Spain.
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